Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magali Terme

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Bulletin Du Cancer|February 25, 2020
[Current advances in immunotherapy in ovarian cancer]Olivia Le Saux, Bertrand Dubois, Marc-Henri Stern, et al.
Oncoimmunology|June 25, 2026
Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinomaFanny Méjean, Thi Tran, Maya Merabet, et al.
Cancer Research|July 19, 2005
BCR/ABL promotes dendritic cell-mediated natural killer cell activationMagali Terme, Christophe Borg, François Guilhot, et al.
Plos One|March 26, 2009
Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15RalphaSophie Viaud, Magali Terme, Caroline Flament, et al.
Plos One|August 13, 2013
Inhibition of the differentiation of monocyte-derived dendritic cells by human gingival fibroblastsSylvie Séguier, Eric Tartour, Coralie Guérin, et al.
Molecular Cancer Therapeutics|October 21, 2024
Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based TherapyAhmad Joshkon, Wael Traboulsi, Magali Terme, et al.
European Journal of Immunology|September 16, 2005
IL-2 production by dendritic cells is not critical for the activation of cognate and innate effectors in draining lymph nodesNoël E C Schartz, Nathalie Chaput, Julien Taieb, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 24, 2006
Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccinesJulien Taieb, Nathalie Chaput, Noël Schartz, et al.
Cancer Research|January 14, 2010
Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligandsRosa Conforti, Yuting Ma, Yannis Morel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 25, 2016
IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 AntagonistsMélanie Desbois, Pauline Le Vu, Clélia Coutzac, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Bulletin Du Cancer|February 25, 2020
[Current advances in immunotherapy in ovarian cancer]Olivia Le Saux, Bertrand Dubois, Marc-Henri Stern, et al.
Oncoimmunology|June 25, 2026
Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinomaFanny Méjean, Thi Tran, Maya Merabet, et al.
Cancer Research|July 19, 2005
BCR/ABL promotes dendritic cell-mediated natural killer cell activationMagali Terme, Christophe Borg, François Guilhot, et al.
Plos One|March 26, 2009
Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15RalphaSophie Viaud, Magali Terme, Caroline Flament, et al.
Plos One|August 13, 2013
Inhibition of the differentiation of monocyte-derived dendritic cells by human gingival fibroblastsSylvie Séguier, Eric Tartour, Coralie Guérin, et al.
Molecular Cancer Therapeutics|October 21, 2024
Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based TherapyAhmad Joshkon, Wael Traboulsi, Magali Terme, et al.
European Journal of Immunology|September 16, 2005
IL-2 production by dendritic cells is not critical for the activation of cognate and innate effectors in draining lymph nodesNoël E C Schartz, Nathalie Chaput, Julien Taieb, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 24, 2006
Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccinesJulien Taieb, Nathalie Chaput, Noël Schartz, et al.
Cancer Research|January 14, 2010
Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligandsRosa Conforti, Yuting Ma, Yannis Morel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 25, 2016
IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 AntagonistsMélanie Desbois, Pauline Le Vu, Clélia Coutzac, et al.
Pageof 5